New Data Suggest Veracyte’s Envisia Genomic Classifier Can Help Predict Disease Progression in Interstitial Lung Disease Patients Treated with Combination Immunosuppressive Therapy
Findings presented at the European Respiratory Society International Congress 2022 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) today announced new data suggesting that the Envisia Genomic Classifier (EGC) can help predict which patients with interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), are likely to have progressive disease that declines with combination immunosuppressive … [Read more…]
